Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
Clinical trial NCT04650581 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04650581
- Sponsor
- Canadian Cancer Trials Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-27
- Primary completion
- 2025-05-23
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.